We are excited to have Lucy Norcliffe-Kaufmann, Ph.D., rejoin the Theravance Biopharma team! Dr. Norcliffe-Kaufmann brings with her a wealth of knowledge and proven expertise in clinical research and autonomic disorders. Her leadership and expertise will be invaluable as we progress our ampreloxetine program through the CYPRESS pivotal Phase 3 clinical trial and, if results are positive, work towards regulatory approval to bring a potential innovative medicine to patients. We are honored to have her on our team and eager to see all that we will achieve together in pursuit of making a difference in patients’ and caregivers’ lives. Welcome, Lucy!
Theravance Biopharma US, Inc.
Biotechnology
South San Francisco, CA 7,714 followers
A biopharmaceutical company focused on delivering Medicines that Make a Difference® in patients’ and caregivers’ lives.
About us
Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media.
- Website
-
http://www.theravance.com/home
External link for Theravance Biopharma US, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, CA
- Type
- Public Company
- Founded
- 2014
- Specialties
- lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development
Locations
-
Primary
901 Gateway Blvd.
South San Francisco, CA 94080, US
-
51 South Richmond Street
The Lennox Building - Suite 101
Dublin, Ireland D02 FK02, IE
Employees at Theravance Biopharma US, Inc.
Updates
-
It was incredible connecting at the 10th Annual Congress of the European Academy! Thank you @European Academy of Neurology #neurology #HomeOfNeurology #EANeurology #10yearsEAN
-
-
Theravance Biopharma will be attending the 10th Annual Congress of the European Academy of Neurology! #ean2024 brings together national neurological societies, individual neurologists and related scientists to speak with one united voice and attracts more than 6,000 delegates each year. We look forward to seeing you there! @European Academy of Neurology #neurology #HomeOfNeurology #EANeurology #10yearsEAN
-
-
Theravance Biopharma is researching an investigational drug aiming to reduce nOH symptoms in people with MSA. Symptoms of nOH frequently impact one’s ability to conduct routine daily activities, especially those requiring standing or walking. Learn more about the Phase 3 CYPRESS study and if it’s right for you by visiting our study website at www.cypress-study.com.
-
-
Theravance Biopharma US, Inc. reposted this
ICYMI: The virtual event hosted by Theravance Biopharma US, Inc. (#TBPH) is now available for replay! The event features Horacio Kaufmann, MD, FAAN (New York University Grossman School of Medicine) and Italo Biaggioni, MD (Vanderbilt Autonomic Dysfunction Center), who discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH. Watch here: https://bit.ly/3wRvQZ9
-
-
Spring into action this May! Symptomatic nOH is a common yet debilitating occurrence in people with MSA. The condition affects approximately 70-90% of those with MSA, with symptoms such as dizziness when transitioning from sitting to standing having a potentially significant impacting quality of life. If you or someone you know diagnosed with MSA experience symptoms of nOH, you may quality to participate in our actively recruiting Phase 3 CYPRESS Study. To learn more, including locations of study centers, please visit our study website at cypress-study.com.
-
-
Theravance Biopharma US, Inc. reposted this
Tune into the virtual KOL event at 10am ET hosted by Theravance Biopharma US, Inc. (#TBPH) featuring important presentations from industry experts and company management on ampreloxetine’s potential for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Register here: https://bit.ly/3wRvQZ9
-
-
On this Clinical Trials Day, let's honor the countless individuals who selflessly dedicate themselves to the advancement of medical science: the participants. Their willingness to step forward, often in the face of uncertainty, embodies the very essence of courage and altruism. Each participant's journey is marked by resilience, hope, and a deep-seated belief in the power of research to transform lives. Today, we express our heartfelt gratitude for their invaluable contributions to the pursuit of knowledge and the betterment of humanity.
-
-
Happy International Nurses Day! Today, we celebrate the invaluable contributions of nurses who tirelessly work to promote health, prevent illness, and provide comfort to those in need. Their kindness, expertise, and selflessness shine brightly, guiding patients and their families through moments of vulnerability with care and compassion. Let's express our heartfelt gratitude nurses everywhere for always helping those in need.
-
-
Theravance Biopharma US, Inc. reposted this
Don’t miss it! Theravance Biopharma US, Inc. (#TBPH) is hosting a virtual KOL event on Thurs. May 23 at 10am ET, including presentations from Company management on the clinical development program for ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor with the potential to be a first-in-class therapy effective in treating a constellation of cardinal symptoms of nOH in MSA patients. Register here: https://brnw.ch/21wJvrv
-
Similar pages
Browse jobs
Stock
TBPH
NASDAQ
20 minutes delay
$8.16
-0.22 (-2.625%)
- Open
- 8.33
- Low
- 8.16
- High
- 8.43
Data from Refinitiv
See more info on